| Without worsening | With worsening | P |
---|---|---|---|
a. Male | n = 139 | n= 17 | Â |
FEV1 (ml) | −25.6 ± 35.5 | −43.2 ± 51.3 | 0.52 |
FEV1 % predicted | −0.12 ± 1.41 | −0.09 ± 2.01 | 0.63 |
FVC (ml) | −35.0 ± 43.0 | −58.5 ± 64.8 | 0.29 |
FVC % predicted | −0.23 ± 1.41 | −0.93 ± 2.02 | 0.32 |
VC (ml) | −39.1 ± 43.4 | −52.9 ± 49.6 | 0.28 |
VC % predicted | −0.60 ± 1.37 | −1.00 ± 1.60 | 0.51 |
FEV1/FVC (%) | −0.04 ± 0.72 | −0.24 ± 1.10 | 0.07 |
b. Female | n = 367 | n = 40 | Â |
FEV1 (ml) | −23.1 ± 25.1 | −30.9 ± 22.3 | <.01 |
FEV1 % predicted | −0.27 ± 1.69 | −0.40 ± 1.29 | <.001 |
FVC (ml) | −31.1 ± 35.0 | −38.5 ± 26.3 | <.05 |
FVC % predicted | −0.19 ± 1.91 | −0.50 ± 1.41 | <.05 |
VC (ml) | −31.4 ± 34.0 | −44.6 ± 30.5 | <.05 |
VC % predicted | −0.60 ± 1.59 | −1.27 ± 1.45 | <.001 |
FEV1/FVC (%) | −0.04 ± 0.73 | −0.16 ± 0.90 | 0.13 |